Cue Biopharma, Inc.
NASDAQ:CUEBiotechnology
+$0.38 today
- Market cap
- $102.43M
- Beta
- 2.53
- P/E (TTM)
- -6.7
- EPS (TTM)
- -$4.06
Volume 0.21M
Average 0.74M
CUE Total Debt
Short-term and long-term borrowings combined.
Cue Biopharma, Inc.NASDAQ: CUE
Total Debt · Q1 FY2026 · quarter ended Mar 2026
Total debt falls 51.7% from a year ago
Total debt stood at $3.44M at the end of Q1 FY2026, down 51.7% from a year earlier and down 18.0% from the prior quarter. Over 3 fiscal years it compounded at -39.9% a year.
Context
- Total debt amounted to 11.1% of total assets at the end of Q1 FY2026, down 20.9 pp from a year earlier.
- Total debt increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total debt keeps falling in the next quarterly balance sheet after a -51.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 4.2M USD
- Year-over-year change
- -52.7%
- 4-year CAGR
- -23.1%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.2M | -52.7% |
| FY2024 | 2024-12-31 | 8.88M | -39.6% |
| FY2023 | 2023-12-31 | 14.7M | -23.9% |
| FY2022 | 2022-12-31 | 19.32M | +60.7% |
| FY2021 | 2021-12-31 | 12.02M | — |
Total Debt vs competitors
How CUE compares with its peers on the latest reported figures
- CUE's Mar 2026 total debt of $3.44M is the 4th highest of the 7 companies compared; the peer median is $4.03M.
- Its year-over-year change of -51.7% is the 5th highest of 7, against a peer median of -13.6%.
- Total debt amounts to 11.1% of total assets for CUE, versus a peer median of 10.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $48.03M | -8.8% | -4.1% | 14.7% | |
| Mar 2026 | $27.19M | -18.4% | +40.2% | 124.2% | |
| Mar 2026 | $7.12M | +210.3% | -51.2% | 12.7% | |
| Mar 2026 | $3.44M | -51.7% | -39.9% | 11.1% | |
| Mar 2026 | $934K | -88.9% | -60.9% | 7.8% | |
| Mar 2026 | $692K | +134.6% | -58.7% | 1.1% | |
| Mar 2026 | $100K | -95.1% | -49.2% | 0.5% | |
| Peer median (excluding CUE) | $4.03M | -13.6% | -50.2% | 10.3% | |
Competitors are the stored peer set for CUE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 64.37M | 51.61M | 48.51M | 22.46M | 27.14M |
| Short-term Investments | 0 | 24.68M | 0 | 929K | 0 |
| Net Receivables | 3.14M | 57K | 1.7M | 945K | 7.45M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 80K | 841K | 1.24M | 805K | 2.4M |
| Total Current Assets | 68.47M | 77.19M | 51.45M | 25.14M | 36.98M |
| Property, Plant & Equipment (Net) | 11.92M | 10.7M | 7.12M | 4.84M | 4.32M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 150K | 0 | 151K | 0 | 154K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 2.86M | 3.39M | 2.81M | 2.21M | 760K |
| Total Non-current Assets | 14.93M | 14.1M | 10.08M | 7.05M | 5.23M |
| Total Assets | 83.4M | 91.28M | 61.53M | 32.19M | 42.21M |
| Account Payables | 2.59M | 2.73M | 3.5M | 2.82M | 3.95M |
| Short-term Debt | 1.97M | 1.96M | 3.96M | 4.33M | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 645.35K | 0 | 2.11M | 0 | 5.34M |
| Other Current Liabilities | 38.31K | 2.27M | 1.92M | 85K | 783K |
| Total Current Liabilities | 12.79M | 11.55M | 17.08M | 13.69M | 13.49M |
| Long-term Debt | 0 | 8.04M | 4.2M | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 1 | 0 |
| Total Non-current Liabilities | 5.12M | 14.05M | 7.36M | 1M | 2.29M |
| Total Liabilities | 17.91M | 25.6M | 24.45M | 14.69M | 15.78M |
| Common Stock | 32.2K | 43K | 47K | 62K | 97K |
| Retained Earnings | (197.45M) | (250.46M) | (301.19M) | (341.86M) | (368.47M) |
| Accumulated OCI | 0 | (96K) | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 65.49M | 65.68M | 37.09M | 17.5M | 26.43M |
| Total Debt | 12.02M | 19.32M | 14.7M | 8.88M | 4.2M |
| Net Debt | (52.35M) | (32.3M) | (33.82M) | (13.58M) | (22.94M) |
Cue Biopharma, Inc.
NASDAQ:CUE
Intrinsic Alpha fair value
Locked
Current Price
$14.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.